IE47791B1 - Stable solutions of hydrogenated ergopeptide alkaloids - Google Patents
Stable solutions of hydrogenated ergopeptide alkaloidsInfo
- Publication number
- IE47791B1 IE47791B1 IE1598/78A IE159878A IE47791B1 IE 47791 B1 IE47791 B1 IE 47791B1 IE 1598/78 A IE1598/78 A IE 1598/78A IE 159878 A IE159878 A IE 159878A IE 47791 B1 IE47791 B1 IE 47791B1
- Authority
- IE
- Ireland
- Prior art keywords
- solution
- component
- weight
- mixture
- water
- Prior art date
Links
- 229930013930 alkaloid Natural products 0.000 title claims description 6
- 239000000203 mixture Substances 0.000 claims abstract description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 26
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 12
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims abstract description 11
- 239000001257 hydrogen Substances 0.000 claims abstract description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 9
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 7
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims abstract description 4
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims abstract description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 39
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 36
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- 239000002904 solvent Substances 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 7
- QHZUABXEBRGBLP-LKWYKXIFSA-N (6aR,9R,10aR)-N-[(2R,4R,9aS,9bR)-4-benzyl-9b-hydroxy-3,5-dioxo-2-propan-2-yl-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide (6aR,9R,10aR)-N-[(2R,4R,9aS,9bR)-9b-hydroxy-3,5-dioxo-2,4-di(propan-2-yl)-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide (6aR,10aR)-N-[(2S,4S,9bS)-9b-hydroxy-4-(2-methylpropyl)-3,5-dioxo-2-propan-2-yl-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)C4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)C)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2CC(CN(C)[C@@H]2C2)C(=O)N[C@@]3(C(=O)C4[C@@H](C(N5CCCC5[C@@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(C21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C(C)C)C1=CC=CC=C1 QHZUABXEBRGBLP-LKWYKXIFSA-N 0.000 claims description 6
- HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 claims description 6
- 229960004704 dihydroergotamine Drugs 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 150000003797 alkaloid derivatives Chemical class 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 239000003708 ampul Substances 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 abstract description 14
- 238000002360 preparation method Methods 0.000 abstract description 4
- PBKVEOSEPXMKDN-LZHUFOCISA-N chembl2311030 Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)C)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)CC)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(N21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C(C)C)C1=CC=CC=C1 PBKVEOSEPXMKDN-LZHUFOCISA-N 0.000 abstract description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 35
- 239000011877 solvent mixture Substances 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000011261 inert gas Substances 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 2
- 229950001817 alpha-ergocryptine Drugs 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- SEALOBQTUQIVGU-QNIJNHAOSA-N dihydroergocornine Chemical compound C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)C)C(C)C)=C3C2=CNC3=C1 SEALOBQTUQIVGU-QNIJNHAOSA-N 0.000 description 2
- 229960004290 dihydroergocornine Drugs 0.000 description 2
- ADYPXRFPBQGGAH-UMYZUSPBSA-N dihydroergotamine mesylate Chemical compound CS(O)(=O)=O.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C)C1=CC=CC=C1 ADYPXRFPBQGGAH-UMYZUSPBSA-N 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010054880 Vascular insufficiency Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- PBUNVLRHZGSROC-VTIMJTGVSA-N dihydro-alpha-ergocryptine Chemical compound C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1 PBUNVLRHZGSROC-VTIMJTGVSA-N 0.000 description 1
- 229960002032 dihydroergocryptine Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229960003133 ergot alkaloid Drugs 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical group 0.000 description 1
- 208000023577 vascular insufficiency disease Diseases 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19772735587 DE2735587A1 (de) | 1977-08-06 | 1977-08-06 | Stabile loesungen und verfahren zu deren herstellung |
Publications (2)
Publication Number | Publication Date |
---|---|
IE781598L IE781598L (en) | 1979-02-06 |
IE47791B1 true IE47791B1 (en) | 1984-06-27 |
Family
ID=6015843
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IE1598/78A IE47791B1 (en) | 1977-08-06 | 1978-08-04 | Stable solutions of hydrogenated ergopeptide alkaloids |
Country Status (23)
Country | Link |
---|---|
JP (1) | JPS5428811A (no) |
AT (1) | AT364463B (no) |
AU (1) | AU525725B2 (no) |
BE (1) | BE869560R (no) |
CA (1) | CA1111348A (no) |
CH (1) | CH635347A5 (no) |
CS (1) | CS203199B2 (no) |
DE (1) | DE2735587A1 (no) |
DK (1) | DK337678A (no) |
FI (1) | FI782341A (no) |
FR (1) | FR2399248A2 (no) |
GB (1) | GB1596948A (no) |
GR (1) | GR72791B (no) |
IE (1) | IE47791B1 (no) |
IL (1) | IL55285A (no) |
IT (1) | IT1202759B (no) |
NL (1) | NL7808122A (no) |
NO (1) | NO147901C (no) |
NZ (1) | NZ188073A (no) |
PT (1) | PT68386A (no) |
SE (1) | SE444114B (no) |
YU (1) | YU188378A (no) |
ZA (1) | ZA784435B (no) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2930369A1 (de) * | 1979-07-26 | 1981-02-05 | Rentschler Arzneimittel | Arzneimittelloesungen |
DE2945636A1 (de) * | 1979-11-12 | 1981-05-21 | Sandoz-Patent-GmbH, 7850 Lörrach | Stabile loesungen von hydrierten ergotalkaloiden bzw. ihren salzen und heparin bzw. seinen salzen sowie verfahren zu deren herstellung |
DE3227122A1 (de) * | 1982-07-20 | 1984-01-26 | Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim | Stabile loesungen von mutterkornalkaloiden |
IT1200609B (it) * | 1985-04-04 | 1989-01-27 | Poli Ind Chimica Spa | Composizione farmaceutice per il trattamento delle turbe cerebrovascolari e del cervello anziano |
GB8629781D0 (en) * | 1986-12-12 | 1987-01-21 | Glaxo Group Ltd | Pharmaceutical compositions |
IL145550A0 (en) * | 1999-03-26 | 2002-06-30 | Pozen Inc | High potency dihydroergotamine compositions |
DE102007014947B4 (de) | 2007-03-23 | 2010-05-27 | Axxonis Pharma Ag | Stabilisierte wässrige Lösungen von Ergolinverbindungen |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3749779A (en) * | 1970-08-27 | 1973-07-31 | American Home Prod | Stable solutions of sodium diphenylhydantoin |
-
1977
- 1977-08-06 DE DE19772735587 patent/DE2735587A1/de not_active Withdrawn
-
1978
- 1978-05-30 GB GB23758/78A patent/GB1596948A/en not_active Expired
- 1978-07-24 CH CH796478A patent/CH635347A5/de not_active IP Right Cessation
- 1978-07-27 FI FI782341A patent/FI782341A/fi not_active Application Discontinuation
- 1978-07-28 NO NO782605A patent/NO147901C/no unknown
- 1978-07-28 DK DK337678A patent/DK337678A/da not_active Application Discontinuation
- 1978-07-28 SE SE7808210A patent/SE444114B/sv unknown
- 1978-08-02 NL NL787808122A patent/NL7808122A/xx not_active Application Discontinuation
- 1978-08-02 IT IT26407/78A patent/IT1202759B/it active
- 1978-08-03 YU YU01883/78A patent/YU188378A/xx unknown
- 1978-08-04 GR GR56936A patent/GR72791B/el unknown
- 1978-08-04 IL IL55285A patent/IL55285A/xx unknown
- 1978-08-04 PT PT68386A patent/PT68386A/pt unknown
- 1978-08-04 BE BE78189738A patent/BE869560R/xx not_active IP Right Cessation
- 1978-08-04 AU AU38676/78A patent/AU525725B2/en not_active Expired
- 1978-08-04 IE IE1598/78A patent/IE47791B1/en unknown
- 1978-08-04 CA CA308,775A patent/CA1111348A/en not_active Expired
- 1978-08-04 AT AT0567378A patent/AT364463B/de not_active IP Right Cessation
- 1978-08-04 NZ NZ188073A patent/NZ188073A/xx unknown
- 1978-08-04 FR FR7823160A patent/FR2399248A2/fr active Granted
- 1978-08-04 ZA ZA784435A patent/ZA784435B/xx unknown
- 1978-08-04 CS CS785139A patent/CS203199B2/cs unknown
- 1978-08-05 JP JP9576378A patent/JPS5428811A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
FI782341A (fi) | 1979-02-07 |
SE444114B (sv) | 1986-03-24 |
AU3867678A (en) | 1980-02-07 |
CS203199B2 (en) | 1981-02-27 |
CA1111348A (en) | 1981-10-27 |
DE2735587A1 (de) | 1979-02-15 |
GB1596948A (en) | 1981-09-03 |
IL55285A0 (en) | 1978-10-31 |
IT7826407A0 (it) | 1978-08-02 |
NL7808122A (nl) | 1979-02-08 |
FR2399248B2 (no) | 1980-07-18 |
ATA567378A (de) | 1981-03-15 |
ZA784435B (en) | 1980-03-26 |
NO147901B (no) | 1983-03-28 |
CH635347A5 (en) | 1983-03-31 |
FR2399248A2 (fr) | 1979-03-02 |
IE781598L (en) | 1979-02-06 |
AT364463B (de) | 1981-10-27 |
JPS5428811A (en) | 1979-03-03 |
IL55285A (en) | 1981-09-13 |
IT1202759B (it) | 1989-02-09 |
SE7808210L (sv) | 1979-02-07 |
NO782605L (no) | 1979-02-07 |
DK337678A (da) | 1979-02-07 |
AU525725B2 (en) | 1982-11-25 |
NZ188073A (en) | 1980-12-19 |
BE869560R (fr) | 1979-02-05 |
PT68386A (en) | 1978-09-01 |
GR72791B (no) | 1983-12-05 |
NO147901C (no) | 1983-07-06 |
YU188378A (en) | 1984-02-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4138565A (en) | Stable solutions and processes for their preparation | |
RU2192249C2 (ru) | Жидкая стабильная композиция на основе парацетамола и способ ее получения | |
CA1177399A (en) | Injectable composition of rapamycin | |
US5047230A (en) | Aerosol composition comprising nitroglycerin as active ingredient | |
CA1251734A (en) | Stabilized injectable solutions of piroxicam | |
NZ198533A (en) | Soft gelatin capsules containing prostaglandins | |
IE47791B1 (en) | Stable solutions of hydrogenated ergopeptide alkaloids | |
GB2250197A (en) | Pyroxycam solutions of increased stability and without tissue-damaging effect | |
US4784855A (en) | Pharmaceutical compositions and suppository | |
EP1352654B1 (en) | Famotidine injections | |
CA1069438A (en) | Stable solutions and processes for their preparation | |
US4402949A (en) | Stable solutions of hydrogenated ergotalkaloids | |
JPH0576929B2 (no) | ||
HU179989B (en) | Process for preparing pharmacological compositions containing r-/+/-1-/1-phenyl-ethyl/-1h-imidazol-5-carboxylic acid ethyl ester for intravenous administration | |
JPH11189531A (ja) | 経粘膜投与用医薬組成物 | |
AU699386B2 (en) | A pharmaceutical composition for lowering the blood pressure and a process for the preparation thereof | |
CA2217360A1 (en) | Package holding a procaterol hydrochloride aqueous solution formulation, and a procaterol hydrochloride aqueous solution formulation | |
CA3133952A1 (en) | Pharmaceutical composition having excellent drug absorption into the living body and excellent chemical stability | |
IE50372B1 (en) | Stable solutions of hydrogenated egotalkaloids | |
US4377583A (en) | N-Methyl-D-glucamine salt of with 3,4-dihydro-5-methyl-6-(2-methylpropyl)-4-oxothieno[2,3-d]pyrimidine-2-carboxylic acid | |
HU181940B (en) | Process for producing solutions of vincane derivatives for parentheral application | |
FR2456101A1 (fr) | Derives dihalogenes geminaux de pyrimidin-4-one condensees, procede pour leur preparation et compositions pharmaceutiques les contenant | |
IE50512B1 (en) | Pharmaceutical injectable composition and two-pack container for said composition | |
CA1282703C (en) | Stable injectable antiemetic compositions | |
AU637801B2 (en) | Intranasal administration of 3,3-disubstituted indolines |